The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (SUPERNOVA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT05648110
Recruitment Status : Active, not recruiting
First Posted : December 13, 2022
Last Update Posted : April 17, 2024
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : September 7, 2023
Estimated Study Completion Date : January 31, 2025
CDC 2021 CDC (Centers for Disease Control and Prevention). General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: Accessed 23 May 2022.
Fact Sheet EUA Bebtelovimab 2022 US Food and Drug Administration. Fact Sheet For Healthcare Providers: Emergency Use Authorization for Bebtelovimab, March 2022. Available at: Accessed 23 May 2022.
NIH 2017 NIH. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Available at: Published 2017. Accessed 23 May 2022.
WHO 2022 World Health Organization. WHO COVID-19 Case definition, July 2022. Available at: 2022.1. Accessed 05 May 2023.
WHO 2023 WHO Coronavirus disease (COVID-19) dashboard. Available at: Accessed 05 June 2023.